X0202 SCHEDULE 13G/A 0001104659-24-023719 0001263508 XXXXXXXX LIVE 2 Common Shares, no par value per share 04/30/2026 0001703057 AbCellera Biologics Inc. 00288U106 150 W 4th Avenue Vancouver A1 V5Y 1G6 Rule 13d-1(b) Baker Bros. Advisors LP DE 33012138.00 0.00 33012138.00 0.00 33012138.00 N 10.8 IA PN Baker Bros. Advisors (GP) LLC DE 33012138.00 0.00 33012138.00 0.00 33012138.00 N 10.8 HC OO Julian C. Baker X1 33012138.00 0.00 33012138.00 0.00 33012138.00 N 10.8 HC IN Felix J. Baker X1 33012138.00 0.00 33012138.00 0.00 33012138.00 N 10.8 HC IN AbCellera Biologics Inc. 150 W 4th Avenue, Vancouver, A1 V5Y 1G6 This Amendment No. 2 to Schedule 13G amends the previously filed Schedule 13G filed by Baker Bros. Advisors LP (the "Adviser"), Baker Bros. Advisors (GP) LLC (the "Adviser GP"), Julian C. Baker and Felix J. Baker (collectively, the "Reporting Persons"). Except as supplemented herein, such statements, as heretofore amended and supplemented, remain in full force and effect. This Amendment No. 2 is being filed jointly by the Reporting Persons. The business address of each of the Reporting Persons is: c/o Baker Bros. Advisors LP 860 Washington Street, 3rd Floor New York, NY 10014 (212) 339-5690 The Adviser is a limited partnership organized under the laws of the State of Delaware. The Adviser GP is a limited liability company organized under the laws of the State of Delaware. The citizenship of each of Julian C. Baker and Felix J. Baker is the United States of America. N IA HC Items 5 through 9 and 11 of each of the cover pages to this Amendment No. 2 are incorporated herein by reference. Set forth below is the aggregate number of common shares ("Common Stock") of AbCellera Biologics Inc. (the "Issuer") directly held by each of Baker Brothers Life Sciences, L.P. ("Life Sciences") and 667, L.P. ("667", and together with Life Sciences, the "Funds") which may be deemed to be indirectly beneficially owned by the Reporting Persons as well as 2,736,200 Common Shares that may be acquired upon exercise of 27,362 European-style call options with a strike price of $0.20 per share ("EUR Call Options"). The EUR Call Options expire on June 12, 2026. The percentage of beneficial ownership for each of the Reporting Persons reported herein and the information set forth below is based on 305,264,947 shares of Common Stock outstanding as of April 15, 2026, as reported in the Issuer's Proxy Statement filed with the Securities and Exchange Commission ("SEC") on April 29, 2026. Such percentage figures are calculated in accordance with Rule 13d-3 under the Securities Exchange Act of 1934, as amended. Pursuant to the management agreements, as amended, among the Adviser, the Funds and their respective general partners, the Funds' respective general partners relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds, and thus the Adviser has complete and unlimited discretion and authority with respect to the Funds' investments and voting power over investments. The Adviser GP is the sole general partner of the Adviser. The Adviser GP, Felix J. Baker and Julian C. Baker as managing members of the Adviser GP, and the Adviser may be deemed to be beneficial owners of securities of the Issuer directly held by the Funds. The Funds beneficially own 33,012,138 shares of Common Stock, including 30,275,938 shares of Common Stock directly held by the Funds and 2,736,200 shares issuable upon the exercise of 27,362 EUR Call Options exercisable within 60 days or 10.8% of the outstanding Common Stock. 667 beneficially owns 0.8% and Life Sciences beneficially owns 10.0% of the outstanding Common Stock. 667 directly holds 2,254,573 shares of Common Stock and 208,900 shares of Common Stock issuable upon exercise of 2,089 EUR Call Options and Life Sciences directly holds 28,021,365 shares of Common Stock and 2,527,300 shares of Common Stock issuable upon exercise of 25,273 EUR Call Options. 0 667 directly holds 2,254,573 shares of Common Stock and 208,900 shares of Common Stock issuable upon exercise of 2,089 EUR Call Options and Life Sciences directly holds 28,021,365 shares of Common Stock and 2,527,300 shares of Common Stock issuable upon exercise of 25,273 EUR Call Options. 0 Y Y N The information in Item 4 is incorporated herein by reference. Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Baker Bros. Advisors LP /s/ Scott L. Lessing 05/07/2026 Baker Bros. Advisors (GP) LLC /s/ Scott L. Lessing 05/07/2026 Julian C. Baker /s/ Julian C. Baker 05/07/2026 Felix J. Baker /s/ Felix J. Baker 05/07/2026